RxDoctor Payments Data

Mark St Martin, MD

Internal Medicine · Novi, MINPI 1922069061

Payments from drug & device makers

$2,025in general payments, 2019–2025

Across 97 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novo Nordisk$256
  • AstraZeneca$241
  • Pfizer$116
  • Amgen$71
  • GSK$50
  • plus $141 from 8 others

What the payments were for

  • Food & beverage$2,01499%
  • Education$111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,025 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$32,123
Medicare patients
214
Services billed
612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide152$181,794
OzempicSemaglutide84$111,093
EliquisApixaban99$100,748
JardianceEmpagliflozin32$46,550
JanuviaSitagliptin Phosphate30$43,647
RybelsusSemaglutide33$40,084
XareltoRivaroxaban24$30,352
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$28,927
FarxigaDapagliflozin Propanediol31$28,308
TrulicityDulaglutide20$28,303
InvokanaCanagliflozin12$19,656
LinzessLinaclotide12$16,625
Breo ElliptaFluticasone/Vilanterol26$13,154
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20$8,512
Atorvastatin Calcium525$6,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$256$151,177117 claims
PfizerEliquis, Paxlovid$116$104,888116 claims
Johnson & JohnsonXarelto, Invokana$1,149$50,00836 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$50$45,04173 claims
AstraZenecaFarxiga, Symbicort$241$32,28349 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Novi

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →